{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:02:02Z","timestamp":1784523722345,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Discordant lymphomas involving mature B-cell and T-cell neoplasms are uncommon and may be missed when atypical clinical manifestations are attributed to a known aggressive lymphoma. We report a 71-year-old man who presented with fever, generalized lymphadenopathy, splenomegaly, splenic infarction, anemia, and thrombocytopenia. Bone marrow, flow cytometry, and tissue immunohistochemistry supported stage IVB diffuse large B-cell lymphoma (DLBCL), non-germinal-center B-cell-like subtype, with bone marrow involvement. After dose-reduced R-CHOPE chemotherapy, partial remission was achieved, but thrombocytopenia and marked splenomegaly persisted. Splenectomy, performed for suspected hypersplenism, unexpectedly showed peripheral T-cell lymphoma with loss of B-cell markers and clonal TCRG and TCRB rearrangements. Ten months after presentation, a right zygomatic-orbital soft tissue lesion was biopsied and confirmed recurrent DLBCL. The patient received R-GemOx plus zanubrutinib, intrathecal chemotherapy, and later R-ICE plus zanubrutinib; however, repeated relapse occurred, and he died 33 months after initial presentation. This case illustrates that persistent splenomegaly, cytopenia, splenic infarction, or anatomically discordant progression during lymphoma treatment should trigger repeat tissue sampling and integrated pathological reassessment. The distinct anatomical distribution, lineage-specific immunophenotypes, and splenic T-cell clonality supported the diagnosis of lineage-discordant lymphoma.<\/jats:p>","DOI":"10.3389\/fonc.2026.1897274","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:32Z","timestamp":1784521232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Discordant diffuse large B-cell lymphoma and splenic peripheral T-cell lymphoma revealed by persistent splenomegaly and cytopenia"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhengying","family":"Ruan","sequence":"first","affiliation":[{"name":"Department of Pathology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmin","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.254.123","article-title":"Incidence patterns of sequential or composite lymphoma: a population-based cancer registry study","volume":"254","author":"Niino","year":"2021","journal-title":"Tohoku J Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1272209","article-title":"Composite diffuse large B-cell lymphoma and peripheral T-cell lymphoma: a case report with two-year follow-up and literature review","volume":"14","author":"Gu","year":"2024","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13289","article-title":"Composite cutaneous lymphoma of diffuse large B-cell lymphoma-leg type and subcutaneous panniculitis-like T-cell lymphoma","volume":"45","author":"Szablewski","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3760\/cma.j.issn.0253-2727.2021.04.014","article-title":"Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma involving the small intestine: a case report","volume":"42","author":"Cao","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0371-9","article-title":"Composite gastrointestinal lymphoma consisting of diffuse large B-cell lymphoma and peripheral T-cell lymphoma","volume":"90","author":"Tachikawa","year":"2009","journal-title":"Int J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.585528","article-title":"Composite primary cutaneous peripheral T-cell lymphoma and Epstein-Barr virus-positive large B-cell lymphoma","volume":"52","author":"Yang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B7","article-title":"Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature","volume":"7","author":"Wang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1309\/VD2D-98ME-MB3F-WH34","article-title":"Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature","volume":"118","author":"Xu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.18038","article-title":"A case of composite lymphoma with extranodal NK\/T-cell lymphoma, nasal-type and diffuse large B-cell lymphoma","volume":"59","author":"Kawai","year":"2019","journal-title":"J Clin Exp Hematop"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-2570(03)00013-3","article-title":"Splenic involvement by peripheral T-cell and NK-cell neoplasms","volume":"20","author":"Chan","year":"2003","journal-title":"Semin Diagn Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12558-015-0373-x","article-title":"A challenging peripheral T-cell lymphoma of the spleen with fatal outcome: A Tunisian case","volume":"7","author":"Attafi","year":"2015","journal-title":"J Afr Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S297539","article-title":"Promising response to lenalidomide-combination therapy in a discordant lymphoma consisting of EBV-positive diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report","volume":"14","author":"Hu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.940513","article-title":"Case report: immune microenvironment and mutation features in a patient with Epstein-Barr virus-positive large B-cell lymphoma secondary to angioimmunoblastic T-cell lymphoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2022.04.029","article-title":"Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma","volume":"25","author":"Grossman","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-021-01425-w","article-title":"EBV-negative angioimmunoblastic T-cell lymphoma with sequential development of diffuse large B-cell lymphoma in course of progression","volume":"37","author":"Petkovic","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00892","article-title":"CD56 in the immune system: more than a marker for cytotoxicity","volume":"8","author":"Van Acker","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S419534","article-title":"Cutaneous methotrexate-related Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with granulomatous cutaneous T-cell lymphoma: a case report and literature review","volume":"16","author":"Kositkuljorn","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"adv00226","DOI":"10.2340\/00015555-3554","article-title":"Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma in patients with erythrodermic cutaneous T-cell lymphoma","volume":"100","author":"Delaleu","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003698","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:34Z","timestamp":1784521234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1897274"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897274","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1897274"}}